Unknown

Dataset Information

Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.


ABSTRACT:

Background

The US Food and Drug Administration (FDA) interchangeability guidelines state that the primary endpoint in a switching study should assess the impact of switching between the proposed interchangeable product and the reference product on clinical pharmacokinetics (PK) and pharmacodynamics (if available), as these assessments are generally sensitive to changes in immunogenicity and/or exposure that may arise due to switching. In addition, interchangeability designation requires no clinically meaningful difference in safety and efficacy of switching between the biosimilar and reference, compared with when using the reference product alone.

Objectives

 The aim of this study was to investigate the PK, immunogenicity, efficacy, and safety in participants undergoing repe

SUBMITTER: Feldman SR 

PROVIDER: S-EPMC10197027 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature